The Low Carb Diabetic

Promoting a low carb high fat lifestyle for the safe control of diabetes. Eat whole fresh food, more drugs are not the answer.


Welcome to the Low Carb Diabetic forum,have you signed up yet? if not then sign up and join us in the low carb community today!

    EMA Will Update SGLT2 Inhibitor Label to Include DKA

    Share
    avatar
    graham64
    Member

    Status :
    Online
    Offline

    Male Posts : 2994
    Join date : 2014-08-10
    Location : Lancs

    EMA Will Update SGLT2 Inhibitor Label to Include DKA

    Post by graham64 on Sun Feb 28 2016, 23:17

    The European Medicines Agency (EMA) has confirmed the recommendations made 2 weeks ago by its Pharmacovigilance Risk Assessment Committee (PRAC) to minimize the risk of diabetic ketoacidosis with use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, a relatively new class of oral medications used to treat type 2 diabetes.

    Following a review of the cases, the EMA has recommended updating the product information of SGLT2 inhibitors licensed in the European Union; these will now list diabetic ketoacidosis as a rare adverse event, affecting up to one in 1000 patients.

    These products include empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), canagliflozin (Invokana, Johnson & Johnson/Janssen), and dapagliflozin (Edistride, Forxiga, AstraZeneca/Bristol-Myers Squibb), and those drugs in combination with metformin under the following trade names: Ebymect, Synjardy, Vokanamet, and Xigduo.

    As the PRAC noted, presentation of DKA in patients taking SGLT2 inhibitors is often atypical, with patients not having blood glucose levels as high as expected, the EMA notes.

    EMA reiterates the advice given by the PRAC regarding the symptoms patients and physicians should watch out for and stresses to doctors that "SGLT2 inhibitors are not authorized for type 1 diabetes," noting that cases of ketoacidosis have occurred "during off-label use and clinical trials in type 1 diabetes."

    But "the benefits of these medicines continue to outweigh the risks in the treatment of type 2 diabetes," EMA concludes.

    http://www.medscape.com/viewarticle/859494?src=rss

    Not to worry peeps the benefits outweigh the risks Cool


    _________________
    I'm a skinny T2 diagnosed 4/4/2008, a high calorie LCHF diet and one metformin a day A1c 6.2 and no complications.

    Proving the LowCarb sceptics wrong for over nine years,

    Not all cherubs are Angels  Wink nor all diabetics Bonkers  Rolling Eyes
    avatar
    chris c
    Member

    Status :
    Online
    Offline

    Posts : 3213
    Join date : 2015-07-26

    Re: EMA Will Update SGLT2 Inhibitor Label to Include DKA

    Post by chris c on Tue Mar 01 2016, 00:00

    Oh yeah, don't forget the UTIs, kidney infections et al. Far preferable to not basing every meal on starchy carbohydrates.

      Current date/time is Tue Sep 26 2017, 06:28